Immunosuppression is a hallmark of tumor progression, and treatments that inhibit or deplete monocytic myeloid-derived suppressive cells could promote anti-tumor immunity. c-FLIP is a central regulator of caspase-8-mediated apoptosis and necroptosis. Here we show that low-dose cytotoxic chemotherapy agents cause apoptosis linked to c-FLIP down-regulation selectively in monocytes. Enforced expression of c-FLIP or viral FLIP rescues monocytes from cytotoxicity and concurrently induces potent immunosuppressive activity, in T cell cultures and in vivo models of tumor progression and immunotherapy. FLIP-transduced human blood monocytes can suppress graft versus host disease. Neither expression of FLIP in granulocytes nor expression of other anti-apoptotic genes in monocytes conferred immunosuppression, suggesting that FLIP effects on immunosuppression are specific to monocytic lineage and distinct from death inhibition. Mechanistically, FLIP controls a broad transcriptional program, partially by NF-κB activation. Therefore, modulation of FLIP in monocytes offers a means to elicit or block immunosuppressive myeloid cells.
T he current treatments for cancer patients rely on cytotoxic agents able to destroy malignant cells 1 that have acquired distinctive chronic proliferation by evading from cell death checkpoints, as well as by self-generating proliferative signals 2 . At the same time, chemotherapy can cause systemic immune modulation at multiple levels 3, 4 . For example, some chemotherapeutics induce immune depression by favoring myelo-and lympho-penia 5 ; on the other hand, chemotherapeutic drugs can exert immune stimulatory actions by favoring the activation of anti-tumor T cells, both through the induction of immunogenic tumor cell death 3, 6 and containment of immunosuppressive immune cell populations, such as regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs) 7, 8 . Chemotherapy can thus be used to restore immune responses in tumor-bearing hosts. Certain pharmacologically active substances can eliminate monocytic (M)-MDSCs in different preclinical models 9 and carboplatin and paclitaxel normalized myeloid cell numbers in advanced cervical cancer patients, increasing the response to a peptide-based vaccine 8 . Considering the many unwanted side effects of chemotherapy, however, definition of the intracellular targets accounting for the exquisite activity of different chemotherapeutics on M-MDSCs is needed for focused molecular approaches. For instance, monocyte/macrophage depletion by trabectedin depends on increased levels of membrane death receptors (Fas and tumor necrosis factor-related apoptosis inducing ligand [TRAIL] receptor 2) that facilitate the recruitment of caspase-8 and the activation of the apoptotic cascade 10 . However, this biological modulation might not be shared by other drugs.
The major player in TRAIL-induced apoptosis resistance is cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) 11 . The gene encoding c-FLIP (CFLAR) is conserved in vertebrates and structurally similar to viral FLICE-inhibitory protein (v-FLIP) that is encoded in the genome of gamma herpesviruses such as the human herpesvirus 8, the Kaposi's sarcoma-associated virus 12, 13 . It is activated by several stimuli, such as growth factors, tumor necrosis factor (TNF)-ligands and chemotherapy and it is transcriptionally regulated, especially by nuclear factor kappalight-chain-enhancer of activated B cells (NF-κB) 14 . In turn, c-FLIP regulates important processes maintaining immune system homeostasis: it protects mature T lymphocytes from activation-induced cell death 15 , it controls Treg homeostasis 16 and survival from FasL-mediating killing by tumor endothelium 17 , as well as Fas sensitivity of monocytes and monocytederived cells, such as dendritic cells (DCs) and macrophages 18, 19 and their viability in the bone marrow during normal development 20 . Recently, c-FLIP expression was shown to represent a conditio sine qua non for tumorinduced, M-MDSC generation 21 .
FLIP expression might buy time for myeloid cells and protect monocytes and macrophages, allowing them to perform their functions in a hostile inflammatory environment. This is likely the case for cancer 21 but it also applies to lung macrophages during post-damage fibrosis 22 ; moreover, FLIP can also limit the negative consequences of caspase-8 activation by inflammasome sensors in macrophages 23 . Thus, FLIP may have acquired other properties during the evolution, contributing more directly to dampen the inflammation in a monocyte/macrophage extrinsic fashion. Here we report a dual role of FLIP in myeloid cells. We found that drugs able to restrain FLIP expression selectively eliminate M-MDSCs but not polymorphonuclear (PMN)-MDSCs restoring T cell responses; more importantly, expression of FLIP in human normal myeloid precursors and monocytes is sufficient to confer the immune suppressive properties associated with MDSCs.
Results c-FLIP protects M-MDSCs from chemotherapy-induced killing. We previously reported that low doses of diverse chemotherapeutic drugs, which are unable to control tumor growth, selectively affect the numbers of circulating CD11b + Ly6G − Ly6C high cells and enhance the efficacy of adoptive cell therapy (ACT) 9 . To understand the molecular basis of this differential susceptibility, we compared 10 conventional anti-cancer drugs to test their ability to modulate in vitro CD11b + Ly6G − Ly6C high cell viability during bone marrow (BM)-MDSC differentiation 24 . After testing different doses of each drug, we defined the highest drug concentration that did not cause overt toxicity, i.e. ≥ 75% of cells were viable at the end of culture ( Supplementary Fig. 1a, b ). Except for fludarabine and carboplatin, the addition of all the tested chemotherapeutics caused a redistribution within the myeloid subsets ( Fig. 1a and Supplementary  Fig. 1c ), characterized by a contraction in CD11b + Ly6G − Ly6C high cells (M-MDSCs) while sparing CD11b + Ly6G + Ly6C low/int cells (PMN-MDSCs). Furthermore, only those drugs effective in reducing M-MDSCs eliminated the immune suppressive activity of cultured cells on activated T lymphocytes ( Fig. 1b) . With a dose-response curve similar to mouse BM-MDSCs, also human CD11b bright cells, which mostly contain PMN-MDSCs, obtained by in vitro culture from bone marrow (BM) Lin − cells in the presence of G-CSF and GM-CSF for four days 25 , survived after exposure to different chemotherapeutics ( Supplementary Fig. 1d , e) at the expense of other fractions and this led to loss of immune suppressive activity, as shown for the drug 5-fluorouracil ( Supplementary Fig. 1f ).
To shed light on the possible mechanisms underlying the cytotoxic action of the diverse chemotherapeutic drugs, we treated MSC2 cells, an immortalized mouse MDSC line 26 , with the minimal effective dose of one agent for each class. All tested drugs activated caspases associated with extrinsic apoptotic pathways, with similar but not overlapping kinetics (Supplementary Fig. 1g ). Moreover, only the addition of a pan-caspase inhibitor to 5-fluorouracil-treated MSC2 cells restored cell viability, whereas no rescue was achieved with a necroptosis inhibitor ( Supplementary Fig. 1h ). Considering the role of c-FLIP in the survival of M-MDSCs but not PMN-MDSCs 21 , we speculated that chemotherapeutics might modulate this antiapoptotic protein. Indeed, Ly6C + cells purified from BM-MDSC cultures after a 24 h treatment with M-MDSC-depleting drugs downregulated the main c-FLIP isoforms, whereas drugs unable to deplete M-MDSCs did not affect c-FLIP RNA expression ( Fig. 1c ). These observations provide evidence for a correlation between FLIP expression and chemotherapy susceptibility in monocytes.
We next verified whether c-FLIP was associated with chemotherapy resistance in human MDSCs. We modified a previously described protocol 25 to generate immunosuppressive MDSCs, which could be infected in vitro by lentiviruses, by culturing BMderived stem cells (CD34 + cells) for four days in the presence of G-CSF and GM-CSF. After the in vitro culture, CD34 + cells differentiated into mature myeloid cells characterized by the downregulation of the CD34 marker and acquisition of myeloid lineage markers (CD33, CD11b, CD15, and CD14) ( Supplementary  Fig. 2a ). During differentiation, cells also acquired immunosuppressive functions typical of MDSCs 27 ( Supplementary Fig. 2b ). We next infected human CD34 + cells with lentiviral expression vectors encoding the two major splice variants of human c-FLIP or luciferase, as negative control, and cultured them in G-CSF and GM-CSF in presence of 5-fluorouracil. The enforced expression of c-FLIP prevented chemotherapy-dependent killing of more mature myeloid cells (CD34 − cells, Fig. 1d ) and preserved their immunosuppressive activity since 5-fluorouracil-treated, c-FLIPinfected cells maintained their ability to arrest in vitro T cell proliferation compared to the control (Fig. 1d ).
These data indicate that chemotherapy-driven elimination of human MDSCs is dependent on c-FLIP modulation. Furthermore, compared to luciferase-expressing cells, untreated c-FLIPexpressing CD34 + cells showed higher suppressive activity toward activated T cells, which was still evident at inhibitor to effector cell ratio as low as 0.1:1 (Fig. 1e ). Therefore, c-FLIP not only controlled myeloid cell survival but also modulated their immune regulatory ability.
v-FLIP + monocytes are chemotherapy-resistant and tolerogenic. To dissect how FLIP proteins regulate myeloid cells we next took advantage of a transgenic (Tg) mouse expressing a form of FLIP from Kaposi's sarcoma virus (hereafter called v-FLIP) 28 . We crossed ROSA26.vFLIP knock-in mice with mice expressing Cre recombinase under the control of the endogenous Lyz2 promoter, thus resulting in mice with v-FLIP expression in the myeloid lineage. In these mice, EGFP is expressed in a common transcript with v-FLIP due to the insertion of an IRES between the two gene sequences 28 . Tg mice (carrying both Cre and v-FLIP genes) were born at the expected Mendelian frequency but showed developmental abnormalities and all the mice died within four weeks ( Supplementary Fig. 3a, b ). Indeed, Tg mice developed a rapid and lethal cachexia associated with systemic immune disorders: hematopoietic dysregulation (higher absolute number of mature CD11b + Ly6G + Ly6C low/int and CD11b + Ly6G − Ly6C high cells), a systemic cytokine storm and massive infiltration of myeloid cells in several organs (Supplementary Fig. 3c-f ), associated with a decrease in CD3 + T cells and preservation of T regulatory (Treg) lymphocytes (Supplementary Fig. 3g, h ). Despite the short life span, these mice allowed us to investigate the relationship between FLIP and chemotherapy in a tumor-free environment. To this end, we added the monocyte-depleting dose of 5-fluorouracil at the beginning of in vitro culture with either wild type (WT) or Tg BM cells and, after four days, determined the absolute numbers of Ly6C + monocytes. Cells with a higher intensity of GFP expression (i.e., cells with higher expression of v-FLIP) survived and were recovered following chemotherapy, compared to those that displayed a lower intensity in GFP ( Fig. 2a ). Furthermore, v-FLIP-BM-MDSCs retained some suppressive ability after the chemotherapy treatment ( Fig. 2b ). We also observed that freshly isolated, v-FLIP-expressing-Ly6C + cells displayed an intrinsically higher suppressive ability compared to the WT monocytes on a per cell basis while v-FLIP-expressing-Ly6G + cells did not show any statistically relevant enhancement in their ARTICLE immunosuppressive function (p = 0.235) ( Fig. 2c ). The difference between v-FLIP-expressing Ly6C + and Ly6G + cells was also demonstrated in vivo. MCA205 tumor-bearing mice were treated with anti-PD − 1 mAb and, later, intravenously transferred with either fresh Ly6C + or Ly6G + cells isolated from the BM of either Tg or WT mice. Only the adoptive cell transfer of v-FLIP-expressing Ly6C + cells was able to abrogate the checkpoint inhibitor efficacy. On the contrary, the transfer of either v-FLIPexpressing-or wild type Ly6G + cells did not result in a statistically significant change (p = 0.667 and p = 0.687, respectively) ( Fig. 2d and Supplementary Fig. 4a ). The suppressive ability of the fresh v-FLIP Tg monocytes was further confirmed in an ACT experimental setting where the infusion of v-FLIP-expressing Ly6C + cells completely abrogated the therapeutic efficacy of OVA-specific T cells in controlling EG7-OVA tumor progression ( Fig. 2e and Supplementary Fig. 4b ). These data indicate that unrestrained expression of v-FLIP, similarly to c-FLIP, is able to confer chemotherapy resistance in Ly6C + cells and reprogram steady-state monocytes to present enhanced immunosuppressive activity.
Human c-FLIP-engineered monocytes induce in vivo tolerance. We next asked whether human mature monocytes could be reprogrammed by c-FLIP expression to become immunosuppressive. Starting from healthy donor (HD) buffy coats, we purified and infected CD14 + monocytes with either c-FLIP-or luciferase-encoding lentiviruses. Also in differentiated CD14 + monocytes, c-FLIP expression increased suppressive activity on stimulated T cells ( Fig. 3a and Supplementary Fig. 5a ). The acquisition of this immune regulatory property did not correlate with a better survival of c-FLIP-expressing monocytes compared to controls, since the percentage of viable (7-AAD − Annexin-V − ) CD14 + cells after in vitro culture, either alone or in the presence of activated T lymphocytes, was comparable during the culture time ( Supplementary Fig. 5b ), indicating that the immune regulatory activity can be separated from the antiapoptotic properties of c-FLIP, at least in the case of mature monocytes. Moreover, the infection of CD14 + cells with lentiviral vectors expressing different anti-apoptotic genes (Bcl-2 or Bcl-xL) 29, 30 did not induce any functional ability to inhibit T cell proliferation ( Supplementary Fig. 5c, d ). Therefore, FLIP is unique in driving the acquisition of immunosuppressive program in monocytes, which is not directly linked to longer survival. Given the strong immune regulatory activity endorsed by FLIP expression, we assessed the ability of c-FLIP-infected CD14 + monocytes to control the graft vs host disease (GvHD) progression in a setting of xenogeneic transplantation. The infusion of c-FLIP-transduced CD14 + cells, controlled established GvHD, resulting in significantly improved long-term survival compared to both untreated mice and mice that received luciferase-expressing CD14 + cells (Fig. 3b ). The infusion of c-FLIP-expressing monocytes also caused a contraction in the number of circulating human CD3 + T cells, provoked the expansion of Tregs and the impairment in IFN-γ production by stimulated CD8 + T cells ( Fig. 3c, d) . The therapeutic impact of the monocyte-induced immune modulation was confirmed by histology and immunohistochemistry (IHC) analyses (Fig. 3e, f and Supplementary Fig. 6a, b ). Human CD14 + cell infiltration was not detected in any of the analyzed tissues, excluding the in vivo persistence of c-FLIP-infected cells after their infusion ( Supplementary Fig. 6c ). Importantly from a clinically relevant translational viewpoint, frozen c-FLIP-expressing monocytes retained their immune modulating activity after thawing and injection in mice; in fact, established GvHD progression was better controlled by the engineered monocytes when compared to thawed human Tregs ( Supplementary Fig. 6d-f ).
FLIP activates a broad inflammatory pathway in myeloid cells.
To investigate the molecular events triggered by enforced c-FLIP expression, we analyzed the transcriptomes of c-FLIP-and luciferase-infected CD14 + cells (GSE101587). The supervised clustering (q.val < 0.05; fold change >2) indicated more than 1100 upregulated genes associated with immune regulation in c-FLIPinfected monocytes compared to control. The list included SOCS2, FAS, CCR7, CCL5, STAT3, CD38, CD274, PDCD1LG2, IL6, IL10, CFS3, PTGS2, IDO1, and IDO2 that are normally activated in MDSCs 27 (Fig. 4a ). By using the gene set enrichment analysis (GSEA), the differentially expressed genes were significantly enriched in categories involved in inflammation, cytokine network and genes up-regulated in response to interferon proteins, as well as associated to the IL-10 pathway and, overall, to NF-κB-related pathway (Fig. 4b) ; these categories were confirmed also by gene ontology (GO) enrichment analysis (Supplementary Fig. 7a, b ). We proved that c-FLIP-transduced CD14 + cells did upregulate both c-FLIP isoforms, i.e. c-FLIP L and c-FLIP S , as well as IDO1, and secreted higher amounts of IL-10 and metabolites of IDO1 enzymatic activity, i.e. kynurenine, when compared to luciferase-transduced CD14 + cells. Furthermore, c-FLIP-expressing monocytes upregulated the surface molecules PD-L2, PD-L1, and CD38, validating gene expression analysis and highlighting a MDSC-like profile (Fig. 4c) .
The enforced expression of FLIP triggers NF-κB pathway. Gene expression data suggested a previously unpredicted transcriptional and signaling activity of c-FLIP, possibly linked to the NF-κB pathway. To elucidate the molecular programs under c-FLIP control, we transiently transfected THP1 monocytic cell line with in vitro transcribed (IVT) c-FLIP-encoding RNA. The rational was to induce a sustained and viral-independent production of the target protein; moreover, the IVT-RNA does not activate innate immunity receptors and type I interferon production 31 . Enforced introduction of a synthetic c-FLIP RNA in THP1 cells triggered an immunosuppressive program consistent with the data shown thus far with lentivirus expression vectors ( Fig. 5a and Supplementary Fig. 8a ). Transfection of c-FLIP RNA significantly promoted the nuclear translocation of the NF-κB subunits p65 and p50, mediators of the canonical NF-κB activation pathway, while no difference in the p52 subunit translocation was detected ( Fig. 5b and Supplementary Fig. 8b ). The kinetics of protein translocation to nucleus and the activation of a reporter gene in THP1-Blue™ cell line induced by c-FLIP RNA transfection demonstrated a strong signaling (with a top activity at 18 h) even though the c-FLIP cytoplasmic localization peaked at 6 h after transfection ( Supplementary Fig. 8c ). Unexpectedly, we observed c-FLIP nuclear translocation ( Fig. 5c ) and, more interestingly, a nuclear co-localization between c-FLIP and p50 ( Fig. 5d ), which might underlie the gene expression induced by FLIP-enforced expression. Also in freshly isolated, v-FLIPexpressing myeloid cells (Ly6C + and Ly6G + cells) we detected a significant nuclear translocation of p65 and p50 proteins compared to WT cells, especially within the monocytic subset ( Supplementary Fig. 8d ). These data indicate that v-FLIP signaling modules are shared with c-FLIP and depend on NF-κB activation in monocytes. To test whether NF-κB signaling was required for the immune regulatory program downstream of FLIP, we demonstrated the ability of NF-κB pathway chemical inhibitors (TPCA-1 and 5Z-7-oxozeanol) to abrogate the immunosuppressive activity of v-FLIP-expressing CD11b + Ly6C + cells isolated from Tg mice and induce a strong downregulation of membrane PD-L1 ( Supplementary Fig. 9a, b ). To provide additional, causative evidence that FLIP-driven immunosuppression is mediated by NF-κB, we silenced the kinases IKKα (encoded by Chuk) and IKKβ (encoded by Ikbkb), alone or in combination ( Supplementary Fig. 9c ) both indispensable for canonical NF-κB activation. We demonstrated that interference with NF-κB pathway was able to restrain partially the immunosuppressive activity as well as the PD-L1 expression in CD11b + Ly6C + cells isolated from either BM of Tg mice ( Supplementary  Fig. 9d , e) or spleen of tumor-bearing wild-type mice (Fig. 5e, f and Supplementary Fig. 9f ). Collectively our data indicate that FLIP activates a signaling pathway that controls the immunosuppressive program in monocytes in part through canonical NF- IDO1  CCL18  CD40  CSF3  IL4R  TNFRSF10B  CFLAR  CCL5  CD38  SOCS2  IL2RA  XIAP  IL6  CCL4  IL10  PDCD1LG2  STAT4  TRAF1  IL12B  TNFRSF21  TNF  CXCL13  SOCS1  FAS  CCR7  NLRP3  CD44  IRAK2  IDO2 κB activation, which directly drives PD-L1 expression. We thus confirm and extend the assumption, supported by longstanding experiments on T lymphocytes, about a direct NF-κB activation by c-FLIP, independent from its anti-apoptotic activity 32 .
FLIP-expressing monocytes in patients with pancreatic cancer.
We assessed c-FLIP expression in blood circulating CD14 + monocytes, by intracellular staining in combination with surface detection of PD-L1, PD-L2, and CD38 ( Supplementary Fig. 10a ). We evaluated cohorts of treatment naïve PDAC (n = 25) and neuroendocrine tumor (NET, n = 5) patients and HDs (patients on oral anticoagulant treatment, n = 25), as a control. Compared to HD, there was a significant increase in the percentage of c-FLIP + CD14 + cells in PDAC but not in NET patients (Fig. 6a ), suggesting that c-FLIP might constitute a biomarker for some cancers. Furthermore, heightened surface expression of PD-L1, PD-L2, and CD38 markers was detected in the cell subset identified as c-FLIP + CD14 + cells, in agreement with our data with genetically-engineered monocytes (Fig. 6b, c and Supplementary  Fig. 10b ). We evaluated the presence of FLIP-expressing monocytes in frozen PBMCs of a second, independent PDAC patient cohort (n = 71) based on the following inclusion criteria: resected pancreatic cancers and treatment naive ( Supplementary Tables 1  and 2 ). Association between the percentage of c-FLIP + CD14 + cells, overall survival (OS) and disease-free survival (DFS) was explored: a positive, but not statistically significant correlation was observed, probably dependent on the sample size (Supplementary Fig. 10c ). However, we demonstrated that PDAC patients with a higher percentage of c-FLIP + PD-L1 + CD14 + cells had significantly shorter OS (p = 0.024) and DFS (p = 0.014) while there was a less significant relationship between FLIP + PD- (Fig. 6d ). Moreover, a statistically significant correlation was found between the combination of high level of serum IL-6 in conjunction with the frequency of c-FLIP + PD-L1 + CD14 + cells and poor OS (p = 0.0014) and DFS (p = 0.036, Fig. 6e ). PD-L1 + expression (Supplementary Fig. 10d ) and IL-6 serum levels alone 33 were only predictive for the OS, but not for DFS; instead, PD-L2 + expression ( Supplementary Fig. 10e ) was not predictive for both OS and DFS. Finally, a multivariate analysis indicated that tumor grade G3 and high IL-6/c-FLIP + PD-L1 + CD14 + cells were negative independent prognostic factors for both OS and DFS in this patient's cohort ( Supplementary Table 3 ).
Discussion
FLIP is an anti-apoptotic regulator that is involved in conferring chemotherapeutic resistance in a wide range of cancers 34 . Our data highlight an inverse correlation between FLIP expression and chemotherapy susceptibility in tolerogenic M-MDSCs both in vivo and in vitro. Tumor-conditioned monocytes, in fact, are so dependent on c-FLIP expression for their survival to be poisoned by treatments reducing the protein expression. We used low doses of different chemotherapeutic drugs, belonging to four classes with diverse mechanisms of action: anti-metabolite agents (5-fluorouracil, gemcitabine), mitotic inhibitors (docetaxel, paclitaxel), alkylating agents (oxaliplatin, cisplatin) and topoisomerase inhibitors (etoposide, irinotecan). All these drugs selectively affected BM-MDSC differentiation, causing a contraction in M-MDSCs (CD11b + Ly6C + cells) and loss of immunosuppression via the extrinsic apoptotic pathway, except for fludarabine and carboplatin. Indeed, fludarabine mainly induces apoptosis via a mitochondria-dependent pathway 35 whereas carboplatin alone has no effect on apoptosis, while it triggers apoptosis via caspase-3 activation in combination with thioridazine 36 . The M-MDSC depletion is mediated by the activation of the caspases cascade belonging to the extrinsic apoptotic pathway and we showed here for the first time, to the best of our knowledge, that c-FLIP is the downstream target of different chemotherapeutics. PMN-MDSCs are likely protected by the exposure to M-MDSC-depleting chemotherapeutics since they do not constitutively require c-FLIP expression for their survival, which instead depends upon Mcl-1 21 .
In addition to influencing cell survival, we clearly defined that c-FLIP directly regulates the tolerogenic properties of monocytes, in part through activation of the canonical NF-κB signaling pathway. Since other anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, are not capable of activating this molecular program, we speculate that FLIP-associated immunosuppression in monocytes is not directly linked to a prolonged survival and thus unveils a previously unrecognized function for this protein. Mouse and human FLIP-expressing monocytes acquired immunosuppressive features able to constrain T cell activation, both in vitro and in vivo. Furthermore, our experiments using a Tg mice, in which the v-FLIP expression was restricted to myeloid cells, demonstrated that FLIP activation during myeloid differentiation induces a severe inflammatory pathology characterized by an unrestrained systemic myeloid cell infiltration that represses B and T cells, resembling the human inflammatory cytokine syndrome (either associated or not with multicentric Castelman disease), a rare heterogeneous disease in part related to Kaposi's sarcoma herpesvirus infection and characterized by an excess of IL-6 secretion 28 . Interestingly, higher IL-6 serum levels and blood circulating c-FLIP + CD14 + PD-L1 + monocytes defined the PDAC patients with worse survival. Beside the pro-inflammatory gene signature, c-FLIP also affected immune regulatory pathways consisting of more than 1100 upregulated genes, which are enriched in categories involved in NF-κB response to TNF, cytokine network, and genes upregulated by IL-6 via STAT3. This specific gene signature may be linked to a "steered" NF-κB activation induced by the nuclear translocation of FLIP. Moreover, the FLIP-associated signature clustered healthy individuals and cancer patients, reflecting the potential involvement of c-FLIP in cancer-induced inflammation. The enumeration of circulating c-FLIP-expressing monocytes, in association with specific surface markers induced by FLIP, such as PD-L1, PD-L2 and CD38 can thus constitute a useful tool to refine the immunological landscape of cancer patients for a more correct diagnosis and treatment. Obviously, it would be important to exploit the efficacy of these markers in cancer settings other than PDAC.
A careful analysis of the growth curves in tumor-bearing mice treated with anti-PD-1 suggest that PD-L1 expression can be responsible only for a part of the immune evasion mediated by the infusion of v-FLIP-expressing monocytes ( Supplementary  Fig. 4a ). Considering the plethora of immune regulatory circuits activated by FLIP, this was largely expected. Our data suggest that targeting FLIP-associated monocytes in combination with checkpoint inhibitors might increase the therapeutic efficacy of cancer immunotherapy.
By contrast to cancer, where depletion of immunosuppressive myeloid cells is sought, the infusion of engineered, FLIPexpressing monocytes might help treating patients with severe GvHD, with clinical advantages over other immunoregulatory cells, such as Tregs. Several reports suggest the potential effect of MDSC-like cells on GvHD control 37 . In a mouse GvHD model, a single early, post-transplant MDSC infusion transiently suppressed but did not eliminate GvHD 38 . This limited activity likely depends on the infusion of incompletely differentiated myeloid cells, which survive in the host after transfusion and differentiate in vivo into antigen presenting cells (APCs), thus limiting the treatment effectiveness. The M-MDSC subset comprises cycling and partially committed precursors 9 that can lose their immunosuppressive ability following activation of AIM2 inflammasome 38 . In our experiments, the therapeutic effect of FLIPexpressing human CD14 + cells was assessed in a stringent experimental model of established GvHD. In fact, infusions of myeloid cells were started when the disease was clearly detected (circulating hCD3 + T cells >5%). FLIP-expressing, human CD14 + cells did not survive in vivo for a long time after transfer, limiting their potential to mature into APCs able to sustain T cell activation. We think that all these combined effects allowed reconditioned hCD14 + monocytes to control disease progression in the host.
We have uncovered a critical dual role of FLIP in myeloid cell physiology. In mature monocytes, cancer-induced FLIP expression promotes immune suppressive functions, prolongs survival and confers chemotherapy susceptibility; on the other hand, constitutive FLIP activation in myeloid lineage fuels a chronic inflammatory syndrome associated with myeloproliferation and immune suppression. Hence, FLIP emerges as a novel candidate for controlling cancer-associated chronic inflammation and immune dysfunction, as well as a target to generate powerful immune modulators of exaggerated, life-threatening immune responses. Indeed, 287 patients admitted at the Unit of General and Pancreatic Surgery of the Azienda Ospedaliera Universitaria Integrata of Verona between 2012 and 2014 with suspected PDAC were assessed for eligibility. Among them, a total of 71 treatment-naïve resectable patients with histologically proven non-metastatic PDAC were included in the study. Inclusion criteria for this study were: histopathological confirmation of PDAC, no prior neo-adjuvant therapy, no evidence of metastatic disease, eligible for surgical resection. Peripheral blood samples were prospectively collected from all patients before surgical resection. Clinic-pathologic features of patients were reported in Supplementary Table 2 and included age, gender, tumor location, tumor size, differentiation status, lymph node involvement and TNM stage, patterns of resection margins, patterns of recurrence. Disease-free survival (DFS) was determined from the time of surgery until local or metastatic PDAC tumor recurrence. Overall survival (OS) was defined as the time of surgery to death. Informed consent was obtained from all subjects. This study was performed in accordance with the ethical standards of the Helsinki Declaration of the World Medical Association. Compliance with REMARK guidelines is reported in Supplementary Table 1 . Survival curves were drawn by Kaplan-Meier estimates and compared by log-rank test. The optimal cutoff thresholds of biomarkers were obtained based on the maximization of the Youden's statistics J = sensitivity + specificity + 1 using an R-based software as described in Budczies et al. 39 . Multivariate analyses were conducted by Cox's proportional hazard regression models using all variables that were significant in univariate analysis (p ≤ 0.05). Statistical analyses were performed using GraphPad Prism software program (version 5.00 for MAC OS X, GraphPad Software, San Diego, California USA, www.graphpad.com), IBM SPSS Statistics (version 24.0 Armonk, NY: IBM Corp.), and the statistical language R. 17 . Lentiviral transduction vector pELNS encoding luciferase was a kind gift from Dr. D. Melisi (University of Verona). We sub-cloned viral FLIP using plasmids available from Addgene (Cambridge, MA, USA) and then the target sequence into pELNS vector.
RNA synthesis. The sequences encoding for GFP, c-FLIP S , c-FLIP L , v-FLIP, eGFP-(2TA)-c-FLIP S , eGFP-(2TA)-c-FLIP L , eGFP-(2TA)-v-FLIP were subcloned in the pST-T7-hAg-MCS-FI-A30LA70 vectors and IVT mRNA were produced as previously described 31, 40 . The 3′ UTR (F-I) of this construct have been shown to enhance stability and translation efficiency, as it has the 100-nucleotide poly(A) tail interrupted by a short linker. Plasmids were linearized with EarI and served as the template for IVT mRNA synthesis using T7 RNA polymerase and a transcription kit (MegaScript, Ambion, Austin, TX, USA). The UTP in the reaction was replaced with 1-methylpseudouridine triphosphate (N1-methylpseudouridine-5′-triphosphate, m1ΨTP) (TriLink). β-S-ARCA(capD1) IVT mRNAs were generated as described elsewhere 41 . Upon IVT mRNA production, single-stranded RNA was enriched by cellulose purification and the absence of double-stranded RNA (dsRNA) was confirmed using the dsRNA-specific mAb J2 (10010200, English and Scientific Consulting) 31 . The quality of the purified dsRNA-free IVT mRNA was assessed by spectrophotometry on a 2100 Bioanalyzer (Agilent), and the mRNA was stored at −80°C.
RNA transfection. THP1 RNA-transfection was performed with the following protocol: THP1 were transfected with GFP, c-FLIP S -GFP, c-FLIP L -GFP, c-FLIP S -GFP + c-FLIP L -GFP (50 + 50%), v-FLIP-GFP mRNAs using VIROMER RED technology (Lipocalyx, Halle, Germany) according to the supplier instructions: 3 × 10 6 THP1 cells were seeded in a well of a 6-well plate at a concentration of 2.5 × 10 6 /ml and received 300 μl of a transfection mix composed by 270 μl of mRNA in Viromer Red buffer (11 ng/μl) and 30 μl of Viromer Red solution (diluted 1/25 in Viromer Red Buffer). For mouse monocyte transfection the following protocol was used: after immuno sorting, 1 × 10 6 Ly6C monocytes were transfected in 1 ml of RPMI 1640 (Life Technologies, Carlsbad, CA, USA) for 4 h with IKKα, IKKβ, or scramble siRNAs using gene silencer technology (GenLantis, San Diego, CA, USA). 4 h post transfection 0.5 ml of media was added. The next day, transfected Ly6C were tested in vitro for their suppressive ability.
Lentivirus production and infection. Self-inactivating replication of viral particles were produced by calcium phosphate-mediated transfection of packaging cells (HEK293T) with the appropriate amounts of transfer plasmid and HIV-1 lentiviral packaging constructs pDEL, pREV, and VSV-G. Supernatants were harvested 48 h after transfection, 0.22 μm filtered, concentrated by ultracentrifugation (50,000 × g; 2,20 h), and titrated by limiting dilution assay in HEK293T.
Human CD34 + cells were infected at a MOI (multiplicity of infection) of 2 with 8 µg/ml of polybrene (Millipore, Billerica, MA, USA) and cultured overnight in a 37°C incubator at 8% CO 2 . Virus-containing media was then removed and replaced with fresh one supplemented with cytokines (G-CSF and GM-CSF at 40 ng/ml each). The cells were then differentiated for 4 days. Human CD14 + cells were infected at a MOI of 1 with 8 µg/ml of polybrene (Millipore, Billerica, MA, USA) for 4 h by spin-inoculation (2000 rpm; 37°C). Transduced cells received fresh media and were incubated overnight in a 37°C incubator at 5% CO 2 .
Real-time PCR. Total RNA from both c-FLIP or luciferase-infected monocytes were isolated by TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). The amount and purity of isolated RNA was analyzed by the ND-1000 Spectrophotometer (NanoDrop Technologies). cDNA was prepared using the Super-Script® VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. Real Time PCR was run using 2x SYBR Green master mix (ABI). All samples were normalized using GAPDH endogenous control primers. Post-qRT-PCR analysis to quantify relative gene expression was performed by the comparative Ct method (2 −ΔΔCt ).
Gene expression. For microarrays of genes regulated by c-FLIP overexpression, we prepared n = 4 biological replicates of c-FLIP overexpressing cells and n = 7 controls. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), and contaminant DNA was removed by RNase-Free DNase Set (Qiagen, Hilden, Germany). RNA quality and purity were assessed on the Agilent Bioanalyzer 2100 (Agilent Technologies, Milano, Italy); RNA concentration was determined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). As control of effective gene modulation and of the whole procedure, we monitored the expression levels of c-FLIP by qPCR prior to microarray hybridization. Labeling and hybridization were performed according to Affymetrix One Cycle Target Labeling protocol on HG-U133 Plus 2.0 arrays (Affymetrix, Thermo Fisher Scientific, Waltham, MA, USA). Microarray data are available at Gene Expression Omnibus under accession GSE101587 (see also Supplementary  Dataset_1 ).
All data analyses were performed in R (version 3.3.1) using Bioconductor libraries (BioC 3.5) and R statistical packages. Probe level signals were converted to expression values using robust multi-array average procedure RMA 42 of Bioconductor affy package and batch-corrected using the ComBat function of Bioconductor sva package. To identify genes associated with c-FLIP overexpression in CD14 + cells (c-FLIP signature), we compared the expression levels of CD14 + cells transfected with c-FLIP with those of control cells using Significance Analysis of Microarray algorithm coded in the same R package 43 . In SAM, we estimated the percentage of false-positive predictions (i.e., false discovery rate, FDR) with 100 permutations and selected as differentially expressed those probe sets with an FDR q-value ≤0.01 and an absolute fold change ≥2. This selection resulted in 1690 probe sets corresponding to 486 unique genes upregulated by c-FLIP (c-FLIP signature; GSE101587) and 523 unique downregulated genes. To functionally annotate genes induced by c-FLIP, we consider the Biological Process Gene Ontology (GO) categories and the GO over-representation test 44 implemented in the Bioconductor cluster Profiler package. GO terms were considered significant at a confidence level of 95% after p-value correction using the Benjamini-Hochberg (BH) procedure.
Over-representation analysis was performed using Gene Set Enrichment Analysis and gene sets of the Biocarta and Hallmark collections from the Broad Institute Molecular Signatures Database (http://software.broadinstitute.org/gsea/ msigdb). GSEA software (http://www.broadinstitute.org/gsea/index.jsp) was applied on log2 expression data of cells transfected with c-FLIP or with control vector. Gene sets were considered significantly enriched at FDR <5% when using Signal2Noise as metric and 1000 permutations of gene sets.
Average signature expression has been calculated as the standardized average expression of all signature genes in sample subgroups. Signature scores have been obtained summarizing the standardized expression levels of signature genes into a combined score with zero mean 45 . The values shown in graphs are thus a dimensional.
